Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung

BMJ Case Reports

Volumn 2016, Issue , 2016, Pages

  Verma, Isha ^a   Modi, Anar ^b   Tripathi, Hemantkumar ^c   Agrawal, Abhinav ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

^b Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; D DIMER; FUROSEMIDE; LIOTHYRONINE; METOPROLOL; NIVOLUMAB; PEMETREXED; THYROGLOBULIN ANTIBODY; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROXINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AWARENESS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CARDIOMEGALY; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIASTOLIC DYSFUNCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DIURESIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERVOLEMIA; LUNG ADENOCARCINOMA; LUNG CONGESTION; MEDICAL HISTORY; MIDDLE AGED; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PAINLESS THYROIDITIS; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SPINE METASTASIS; TACHYCARDIA; THORAX RADIOGRAPHY; THYROIDITIS; THYROTOXICOSIS; ADENOCARCINOMA; CHEMICALLY INDUCED; COMPLICATION; LUNG TUMOR;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; THYROIDITIS; THYROTOXICOSIS;

EID: 84956680142     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2015-213692     Document Type: Article

References (16)

1. Sarlis NJ, Gourgiotis L. Thyroid emergencies. Rev Endocr Metab Disord 2003;4:129-36.
2. Ginsberg J, Walfish PG. Post-partum transient thyrotoxicosis with painless thyroiditis. Lancet 1977;1:1125-8.
3. Papadopoulos KI, Hallengren B. Polyglandular autoimmune syndrome type II in patients with idiopathic Addison's disease. Acta Endocrinol (Copenh) 1990;122:472-8.
4. Colao A, Pivonello R, Faggiano A, et al. Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) 2000;53:13-19.
5. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. New Engl J Med 2003;348:2646-55.
6. Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic Malignancies. J Clin Endocrinol Metab 2015;100:1738-41.
7. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endoc Relat Cancer 2014;21:371-81.
8. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012;366:2443-54.
9. Narita T, Oiso N, Taketomo Y, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving Nivolumab. J Dermatol 2015;42:1-5.
10. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 2015;372:320-30.
11. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014;11:91-9.
12. Haanen JB, Thienen Hv, Blank, CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 2015;42:423-8.
13. http://news.bms.com/press-releatse/checkmate-025-pivotal-phase-iii-opdivonivolumabrenal-cell-cancer-trial-stopped-early (accessed 14 Sep. 2015).
14. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Stephanie L. http://emedicine.medscape.com/article/125648-treatment#d10 (accessed 11 Nov. 2015).